Gene set enrichment analysis of HGAL interacting proteins
Gene set | No. of genes in set | Overlap with HGAL interactome | –log10 (FDR) |
---|---|---|---|
GO_CYTOSKELETON | 1967 | 30 | 14.91 |
GO_CELL_JUNCTION | 1151 | 22 | 12.19 |
GO_CELL_LEADING_EDGE | 350 | 14 | 11.19 |
WANG_TUMOR_INVASIVENESS_UP | 374 | 14 | 10.86 |
GO_CYTOSKELETAL_PART | 1436 | 21 | 9.64 |
GO_CELL_PROJECTION | 1786 | 22 | 8.85 |
GO_IMMUNE_SYSTEM_PROCESS | 1984 | 22 | 8.10 |
GO_CYTOSKELETAL_PROTEIN_BINDING | 819 | 15 | 7.79 |
GO_ACTIN_CYTOSKELETON | 444 | 12 | 7.76 |
GO_ACTIN_BINDING | 393 | 11 | 7.15 |
GO_CYTOSKELETON_ORGANIZATION | 838 | 14 | 6.72 |
GO_LAMELLIPODIUM | 172 | 8 | 6.52 |
GO_MICROTUBULE_CYTOSKELETON | 1068 | 15 | 6.37 |
FDR: false discovery rate; GO: gene ontology
Note. Reprinted from “HGAL inhibits lymphoma dissemination by interacting with multiple cytoskeletal proteins,” by. Jiang XY, Lu XQ, Gentles AJ, Zhao DK, Wander SA, Zhang Y, et al. Blood Adv. 2021;5:5072–85 (https://doi.org/10.1182/bloodadvances.2021004304). CC BY NC ND.
We thank to Sylvester Comprehensive Cancer Center for its continuous support over the years that included access to facilities and funding.
XJ and ISL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing—original draft. ISL: Funding acquisition, Project administration, Resources, Supervision, Writing—review & editing.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
ISL was approved by National Cancer Institute [1R01CA233945, U01CA195568], University of Miami SCCC (the Intramural Funding Program), Dwoskin and Anthony Rizzo Families Foundations and Jaime Erin Follicular Lymphoma Research Consortium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2023.